Marcain (Bupivacaine)

Bupivacaine blocks voltage‑gated sodium channels on nerve membranes, preventing sodium influx that is required for depolarisation. By inhibiting the generation and propagation of action potentials, it stops pain signals from reaching the brain, resulting in a reversible loss of sensation in the targeted region.

The dose of Marcain is determined by the prescribing clinician based on the type of procedure, patient weight, age, and health status. Dosage may vary for epidural versus infiltration techniques, and the prescriber will calculate the appropriate volume and concentration to achieve safe and effective anesthesia.

Safety data for bupivacaine during pregnancy and lactation are limited. It may be used when the benefit to the mother outweighs potential risks to the fetus, but clinicians typically exercise caution, especially in the first trimester. Breastfeeding mothers should discuss use with their healthcare provider.

To order Marcain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Both Marcain (bupivacaine) and lidocaine are amide‑type local anesthetics, but bupivacaine has a longer duration of action and higher potency, making it preferable for procedures requiring prolonged analgesia. Lidocaine acts faster but wears off sooner, and it carries a lower risk of cardiotoxicity at equivalent doses.

Marcain should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The vial should remain in its original packaging until use, and any unused portion should be discarded according to local regulations to maintain sterility and potency.

Marcain is administered by a qualified healthcare professional via epidural catheter, spinal needle, or direct infiltration into tissue. The solution is injected slowly, with aspiration before each dose to avoid intravascular delivery, and the volume is adjusted to achieve the desired level of anesthesia while monitoring the patient closely.

The most serious risks include cardiotoxicity (arrhythmias, cardiac arrest) and central nervous system toxicity (seizures, loss of consciousness). Early signs such as metallic taste, tinnitus, or visual disturbances should prompt immediate assessment, and emergency measures must be ready to manage severe cardiac or neurological events.

Marcain should be avoided in patients with known hypersensitivity to bupivacaine or other amide‑type local anesthetics, those with severe cardiac conduction disorders, uncontrolled epilepsy, or significant hepatic impairment that could impair drug metabolism. It is also contraindicated when accidental intravascular injection is likely.